Skip to main content
    A

    Ardelyx Inc (ARDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.07
    -0.02 (-0.65%)

    Market Cap: $776.74M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Ardelyx Inc (ARDX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Ardelyx (ARDX) to earn -$0.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $482.24M. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy19.1%
    Buy1090.9%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 26.1%.

    Fiscal year ending Dec 31, 2026
    -$0.20
    EPS consensus, revenue $482.24M
    Fiscal year ending Dec 31, 2027
    $0.16
    EPS consensus, revenue $608.01M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.20-$0.23 to -$0.187$482.24M$472.88M to $491.56M11
    Dec 31, 2027$0.16$0.04 to $0.497$608.01M$550.50M to $678.53M11

    Quarterly Estimates

    The EPS consensus falls from $0.04 for the quarter ending Dec 31, 2026 to -$0.05 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.04$0.02 to $0.0613$142.01M$127.28M to $155.98M13
    Mar 31, 2027-$0.05-$0.08 to -$0.024$115.82M$101.60M to $122.17M6

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 4 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202611
    Fiscal year ending Dec 31, 202702
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.07.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.20-$0.19-$0.19-$0.20-$0.07N/A
    Fiscal year ending Dec 31, 2027$0.16$0.29$0.29$0.25$0.49-67.9%
    Quarter ending Mar 31, 2027-$0.05-$0.04-$0.04-$0.03-$0.02N/A

    Frequently Asked Questions About ARDX

    What is the ARDX stock forecast?

    Consensus analyst estimates put Ardelyx's EPS at -$0.20 for the fiscal year ending Dec 31, 2026, on revenue of $482.24M. The consensus rating from 11 analysts is Buy.

    How do analysts rate ARDX stock?

    Of 11 analysts covering Ardelyx, 1 rates it Strong Buy, 10 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ARDX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.20, with estimates from -$0.23 to -$0.18 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.16, with estimates from $0.04 to $0.49 from 7 analysts.

    What revenue do analysts expect from Ardelyx next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $482.24M, with estimates from $472.88M to $491.56M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $608.01M, with estimates from $550.50M to $678.53M.

    How many analysts cover ARDX?

    11 analysts rate Ardelyx stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.